By selecting a country, you will see contents with local focus. Contents that are not available in the local language, will be shown in English.

- Our Company
  
  We at AOP Orphan are European pioneers in the field of rare diseases, researching, developing, producing, and distributing innovative solutions worldwide since 1996. Learn more about the company here.
  About Our Company
- Rare And Special Diseases
  
  We at AOP Orphan focus on rare and special diseases particularly in the areas of HematoOncology, Cardiology & Pulmonology, Neurology & Metabolic Disorders and Intensive Care. Learn more about the indications, its symptoms, diagnosis, therapies and everyday life here.
  About Rare And Special Diseases
  - HematoOncology
    - Essential Thrombocythemia
    - Polycythaemia Vera
  - Cardiology & Pulmonology
  - Neurology & Metabolic Disorders
  - Intensive Care
- Individual Treatments
  
  Our strategic goal at AOP Orphan is to constantly deliver new treatment options for the patients with rare disease. Learn more about the current product portfolio and countries' availability here.
  About Individual Treatments
  - HematoOncology
    - Anagrelide AOP
    - BESREMi®
  - Cardiology & Pulmonology
    - Rapibloc®
    - Tadalalfil AOP
  - Neurology & Metabolic Disorders
  - Intensive Care
- Join Us
  
  Agile, ambitious and aligned team members, mutual appreciation and commitment - this is what makes AOP Orphan a successful company and great place to work. Learn more about the company, open positions and everyday life at AOP Orphan here.
  About Join Us
  - HR Contacts
  - Jobs

product details

BESREMi®

Ropeginterferon alfa-2b

Product Details

BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.

BESREMi® 250 micrograms/0.5 mL solution for injection in pre-filled pen

BESREMi® 500 micrograms/0.5 mL solution for injection in pre-filled pen

Ropeginterferon alfa-2b